CLINICAL OUTCOMES OF IVERMECTIN IN COVID-19 TREATMENT: AN EVIDENCE-BASED CASE REPORT FROM SYSTEMATIC REVIEWS AND META-ANALYSES

JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Pub Date : 2021-11-30 DOI:10.53366/jimki.v9i2.411

Jason Theola, Muhammad Ikrar Hermanadi, Kahlil Gibran, Syarifaha Ihsan

{"title":"CLINICAL OUTCOMES OF IVERMECTIN IN COVID-19 TREATMENT: AN EVIDENCE-BASED CASE REPORT FROM SYSTEMATIC REVIEWS AND META-ANALYSES","authors":"Jason Theola, Muhammad Ikrar Hermanadi, Kahlil Gibran, Syarifaha Ihsan","doi":"10.53366/jimki.v9i2.411","DOIUrl":null,"url":null,"abstract":"Background: Ivermectin has demonstrated beneficial results on clinical outcomes in COVID-19 patients. Several countries have included ivermectin in their guidelines, though WHO recommended against its usage. Therefore, this study was aimed to establish the clinical outcomes of ivermectin in COVID-19 patients by an evidence-based method. \nMethod: Article searching was completed in PubMed, Cochrane, and Scopus from July 9 - 10 2021. The results were limited to only systematic reviews and meta-analyses. Hand searching was conducted to obtain relevant studies from external resources. The results were evaluated using inclusion and exclusion criteria. The full texts were obtained and critically reviewed using Oxford Centre for Evidence-Based Medicine critical appraisal tools. \nResult: Three systematic reviews and meta-analyses were selected and critically reviewed. All three studies were considered valid, important, and applicable. However, the quality of these studies varied from low to high. \nConclusion: Overall studies showed that ivermectin has the potential to improve clinical outcomes in COVID-19 patients.","PeriodicalId":14697,"journal":{"name":"JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53366/jimki.v9i2.411","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Ivermectin has demonstrated beneficial results on clinical outcomes in COVID-19 patients. Several countries have included ivermectin in their guidelines, though WHO recommended against its usage. Therefore, this study was aimed to establish the clinical outcomes of ivermectin in COVID-19 patients by an evidence-based method. Method: Article searching was completed in PubMed, Cochrane, and Scopus from July 9 - 10 2021. The results were limited to only systematic reviews and meta-analyses. Hand searching was conducted to obtain relevant studies from external resources. The results were evaluated using inclusion and exclusion criteria. The full texts were obtained and critically reviewed using Oxford Centre for Evidence-Based Medicine critical appraisal tools. Result: Three systematic reviews and meta-analyses were selected and critically reviewed. All three studies were considered valid, important, and applicable. However, the quality of these studies varied from low to high. Conclusion: Overall studies showed that ivermectin has the potential to improve clinical outcomes in COVID-19 patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

伊维菌素治疗COVID-19的临床结果:来自系统评价和荟萃分析的循证病例报告

背景:伊维菌素已证明对COVID-19患者的临床结果有益。一些国家已将伊维菌素纳入其指导方针，尽管世卫组织建议不要使用它。因此，本研究旨在通过循证方法确定伊维菌素在COVID-19患者中的临床疗效。方法:于2021年7月9 - 10日在PubMed、Cochrane和Scopus中完成文章检索。结果仅限于系统评价和荟萃分析。通过手工检索从外部资源中获取相关研究。采用纳入和排除标准对结果进行评价。全文获得并使用牛津循证医学中心的关键评估工具进行了严格审查。结果:选择了三个系统综述和荟萃分析，并对其进行了批判性评价。所有三项研究都被认为是有效的、重要的和适用的。然而，这些研究的质量高低不一。结论:总体研究表明，伊维菌素有改善COVID-19患者临床结局的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia

自引率

0.00%

发文量